Mammography Imbroglio Makes Case For More Stakeholder Input In CER - AHRQ's Clancy
This article was originally published in The Pink Sheet Daily
The AHRQ director reflected on lessons to be learned from the negative public reaction to the U.S. Preventive Services Task Force's opinion on mammography screening.
You may also be interested in...
Current comparative research lacks firm quality data standards, including what would be considered accurate CER. Caplan notes that in today’s research environment, standards are determined by the peer review process and have no consistent application and no regulation. Before asymmetry can be addressed, these standards need to be determined.
Comparative effectiveness research led by a non-government institute with funding from public and private sources, as envisioned by Sen. Max Baucus, D-Mont., is among the provisions for health care reform that are being debated by the Senate, but some changes to CER provisions were made as the bill moved from the Finance Committee to its current iteration on the Senate floor
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.